Israel - hebreo - Ministry of Health

taro international ltd, israel - erlotinib as hydrochloride - טבליות מצופות פילם - erlotinib as hydrochloride 150 mg - erlotinib

Israel - hebreo - Ministry of Health

taro international ltd, israel - erlotinib as hydrochloride - טבליות מצופות פילם - erlotinib as hydrochloride 25 mg - erlotinib

Israel - hebreo - Ministry of Health

teva israel ltd - pemetrexed as diacid monohydrate - תרכיז להכנת תמיסה לאינפוזיה - pemetrexed as diacid monohydrate 25 mg / 1 ml - pemetrexed

Israel - hebreo - Ministry of Health

astrazeneca (israel) ltd - osimertinib as mesylate - טבליה - osimertinib as mesylate 40 mg - osimertinib

Israel - hebreo - Ministry of Health

astrazeneca (israel) ltd - osimertinib as mesylate - טבליה - osimertinib as mesylate 80 mg - osimertinib

Israel - hebreo - Ministry of Health

tzamal bio-pharma ltd - gemcitabine as hydrochloride - אבקה להכנת תמיסה לאינפוזיה - gemcitabine as hydrochloride 200 mg - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Israel - hebreo - Ministry of Health

tzamal bio-pharma ltd - gemcitabine as hydrochloride - אבקה להכנת תמיסה לאינפוזיה - gemcitabine as hydrochloride 1000 mg - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer.gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Israel - hebreo - Ministry of Health

tzamal bio-pharma ltd - gemcitabine as hydrochloride - אבקה להכנת תמיסה לאינפוזיה - gemcitabine as hydrochloride 1500 mg - gemcitabine - gemcitabine - gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin.gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine monotherapy can bee considered in elderly patients or those with performance status 2. gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum - based, first- line therapy. gemcitabine in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemothe

Israel - hebreo - Ministry of Health

novartis israel ltd - gemcitabine as hydrochloride - תרכיז להכנת תמיסה לאינפוזיה - gemcitabine as hydrochloride 40 mg / 1 ml - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Israel - hebreo - Ministry of Health

abic marketing ltd, israel - gemcitabine as hydrochloride - תרכיז להכנת תמיסה לאינפוזיה - gemcitabine as hydrochloride 40 mg/ml - gemcitabine - gemcitabine - gemcitabine teva® concentrate is indicated for the palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer.gemcitabine teva® concentrate is indicated for the treatment of patients with bladder cancer at the invasive stage.breast cancer:gemcitabine teva® concentrate in combination with paclitaxel,is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant /neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.ovarian cancer:gemcitabine teva® concentrate in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma who have relapsed at least 6 months after platinum-based therapy.